Azurity, Takeda & Arbor v. Alkem Laboratories: EDARBYCLOR® Patent Dispute Consolidated in Delaware
Three pharmaceutical plaintiffs — Azurity Pharmaceuticals, Takeda Pharmaceutical, and Arbor Pharmaceuticals — sued Alkem Laboratories in Delaware over five Orange Book-listed patents protecting EDARBYCLOR®, an azilsartan medoxomil/chlorthalidone combination tablet. The case was consolidated with a parallel Saba Ilac action into lead case 22-353-MN for joint administration through trial.
Five-patent EDARBYCLOR® ANDA dispute folded into Delaware consolidated action
On July 15, 2022, Azurity Pharmaceuticals, Takeda Pharmaceutical Company Limited, and Arbor Pharmaceuticals filed suit against Alkem Laboratories Ltd. in the District of Delaware (Civil Action No. 1:22-cv-00940-MN), asserting infringement of five Orange Book-listed patents covering EDARBYCLOR® — an oral tablet combining 40 mg azilsartan medoxomil and 12.5 mg or 25 mg chlorthalidone used in the treatment of hypertension. The action was triggered by Alkem’s ANDA filing seeking approval to market a generic equivalent.
By November 2022, the parties stipulated under Federal Rule of Civil Procedure 42(a) to consolidate the Alkem action with a related case against Saba Ilac Sanayii ve Ticaret AS (Civil Action No. 22-353-MN), filed earlier in March 2022. Civil Action No. 22-353-MN was designated the lead case, and all future filings — including those arising from the Alkem dispute — are now made exclusively under that docket. The Basis of Termination for this docket (22-cv-00940) is recorded as ‘Other,’ reflecting administrative consolidation rather than a substantive dismissal or judgment.
The speed of consolidation — within approximately four months of filing — is consistent with plaintiffs and defendants recognising overlapping patents and shared legal issues early, making joint administration the most cost-effective path. Because the case migrated to the lead docket, the full merits, including claim construction, validity challenges, and infringement findings, remain pending or were addressed in 22-353-MN. The public record for this docket does not disclose settlement terms or any substantive ruling on the five asserted patents.
Filing to filing in 567 days
Days from filing (Jul 2022) to consolidation order (Nov 2022)
Full party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Azurity Pharmaceuticals, Inc. | Company | Pharmaceutical IP coalition — holders of five Orange Book patents covering EDARBYCLOR®Search in Eureka ↗ |
| Defendant | Alkem Laboratories, Ltd. | Company | Alkem Laboratories Ltd. — Indian generic pharmaceutical manufacturer seeking U.S. ANDA approvalSearch in Eureka ↗ |
| Plaintiff counsel | Daniel M. Silver | Attorney | Counsel for Azurity Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Dominick T. Gattuso | Attorney | Counsel for Alkem Laboratories, Ltd.Search in Eureka ↗ |
| Defendant counsel | Gary J. Speier | Attorney | Counsel for Alkem Laboratories, Ltd.Search in Eureka ↗ |
| Defendant counsel | Jennell C. Bilek | Attorney | Counsel for Alkem Laboratories, Ltd.Search in Eureka ↗ |
| Defendant counsel | Samuel T. Lockner | Attorney | Counsel for Alkem Laboratories, Ltd.Search in Eureka ↗ |
| Defendant counsel | Saukshmya Trichi | Attorney | Counsel for Alkem Laboratories, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge Unassigned | Chief Judge | Delaware District Court — Chief JudgeSearch in Eureka ↗ |
Stipulation of dismissal — official text
The operative document is a consolidation stipulation, not a merits verdict. Its legal effect is administrative: docket 22-940 closes and all proceedings — discovery, claim construction, motions, and trial — proceed exclusively under lead case 22-353-MN. For Alkem, this means no dismissal of claims and no relinquishment of defenses; it remains a full defendant in the consolidated action. For plaintiffs, consolidation preserves all five patent assertions against Alkem while achieving procedural efficiency alongside the Saba Ilac dispute.
US7157584B2 and four further patents — azilsartan medoxomil combination antihypertensive
The five asserted patents — US7157584B2, US9169238B2, US7572920B2, US9066936B2, and US9387249B2 — are listed in the FDA Orange Book as covering EDARBYCLOR®, a fixed-dose combination of azilsartan medoxomil (an angiotensin II receptor blocker) and chlorthalidone (a thiazide-like diuretic) indicated for hypertension. The application numbers span filings from the mid-2000s through the early 2010s, suggesting a portfolio built to protect the compound, formulation, and therapeutic use dimensions of the product across its commercial lifecycle.
For the antihypertensive drug sector, a five-patent Orange Book cluster around a single combination product represents a significant exclusivity fortress. Each patent layer — compound, salt form, formulation, and method of treatment — must be independently challenged by any generic entrant under Paragraph IV. The involvement of Takeda as a co-plaintiff underscores the originator-licensee structure common in branded pharmaceutical ANDA litigation, where patent rights may be held across multiple entities with aligned commercial interests in blocking generic entry.
Should your ANDA or generic product team run an FTO against these five EDARBYCLOR® patents?
Any pharmaceutical company developing a generic azilsartan medoxomil/chlorthalidone combination tablet — or any fixed-dose antihypertensive product with overlapping active ingredients or formulation approaches — should treat these five Orange Book patents as an active enforcement risk. The consolidated litigation demonstrates that the patent holders are prepared to litigate simultaneously against multiple generic challengers, and the Delaware district court is a well-resourced forum for Hatch-Waxman disputes.
PatSnap Eureka’s FTO Search Agent allows formulation and regulatory teams to map claim scope across all five asserted patents against your proposed ANDA product specifications before filing. Eureka’s claim monitoring alerts you if continuation or divisional applications related to these patent families publish — a critical signal in Hatch-Waxman contexts where new claims can extend litigation exposure beyond original Orange Book listings. Run your analysis before submitting your Paragraph IV certification.
Run a freedom-to-operate analysis on US7157584B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman ANDA patent cases in Delaware — azilsartan and combination antihypertensives
PatSnap Eureka tracks related litigation across truck body equipment, vehicle accessories, and comparable infringement actions in the Georgia district system.
What this case signals for the Hatch-Waxman antihypertensive IP landscape
Multiple Orange Book patents, multiple generic challengers, and a consolidated Delaware trial — EDARBYCLOR® exclusivity is actively contested.
Five-patent Orange Book listings create layered generic entry barriers
The five asserted patents span multiple application families, suggesting protection across compound, formulation, and possibly method-of-use dimensions for azilsartan medoxomil combinations. Generic entrants must design around or invalidate each layer — a materially higher threshold than single-patent ANDA litigation. Companies developing combination antihypertensive generics should map each asserted patent’s claim scope independently.
Delaware consolidation signals plaintiff confidence in portfolio coherence
Agreeing to consolidate all defendants into one trial — rather than settling with weaker challengers first — typically suggests plaintiffs believe their patent portfolio is defensible across all asserted claims. For IP teams monitoring EDARBYCLOR® freedom to operate, the consolidated claim construction record in 22-353-MN will be the critical document to watch as it will bind all defendants simultaneously.
Azurity v Alkem — key questions answered
Docket 1:22-cv-00940 was administratively closed after the parties stipulated to consolidate the Alkem action with a parallel case against Saba Ilac (22-353-MN) under FRCP 42(a). All proceedings, including trial, continue under lead case 22-353-MN. No merits ruling was issued in this docket.
Five Orange Book patents are asserted: US7157584B2, US9169238B2, US7572920B2, US9066936B2, and US9387249B2. All are listed as covering EDARBYCLOR® (40 mg azilsartan medoxomil with 12.5 mg or 25 mg chlorthalidone oral tablets) in the FDA Orange Book.
The docket was closed due to consolidation under FRCP 42(a), not dismissal or settlement. The Basis of Termination is recorded as ‘Other.’ Substantive claims against Alkem remain live and are being litigated in the consolidated lead case, Civil Action No. 22-353-MN in the District of Delaware.
The plaintiffs are Azurity Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, and Arbor Pharmaceuticals LLC — collectively the Orange Book patent holders or licensees for EDARBYCLOR®. They are represented by McCarter & English LLP in Delaware.
FRCP 42(a) consolidation merges proceedings for efficiency but does not dismiss or waive any claims or defenses. Alkem retains all invalidity and non-infringement arguments. The consolidated trial will address Alkem’s ANDA product alongside Saba Ilac’s, with a single claim construction record binding both defendants.
PatSnap Eureka searches patents and litigation data to answer instantly.